Stand-alone blood clot treatment works as well as standard therapy

07/22/2013 |

A clinical trial found a 2.3% incidence of venous thromboembolism in a group of patients taking the drug apixaban, compared with 2.7% in the group receiving enoxaparin and warfarin. Major bleeding occurred in 9.7% of patients in the standard treatment group and 4.3% of patients in the apixaban group. The study in the New England Journal of Medicine concluded that apixaban was as safe and effective as standard therapy in treating blood clots.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Fremont, CA